(Q40383793)

20 September 2017

1 reference

title

Treatment of inherited coagulation disorders (English)

1 reference

20 September 2017

Cohen AJ

1

1 reference

20 September 2017

Kessler CM

series ordinal

2

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 December 1995

1 reference

American Journal of Medicine

20 September 2017

published in

1 reference

20 September 2017

volume

99

1 reference

20 September 2017

issue

6

1 reference

20 September 2017

page(s)

675-682

1 reference

Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980256-3

Characteristic mRNA abnormality found in half the patients with severe haemophilia A is due to large DNA inversions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980256-3

Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980256-3

Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980256-3

Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980256-3

B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentrates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980256-3

Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate. Multicenter Hemophilia Cohort Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980256-3

Factor IX concentrates for clinical use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980256-3

Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980256-3

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980256-3

Correction of the platelet abnormality in von Willebrand's disease by cryoprecipitate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980256-3

Response of patients with mild and moderate hemophilia A and von Willebrand's disease to treatment with desmopressin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980256-3

10.1016/S0002-9343(99)80256-3

7 January 2021

Identifiers

DOI

1 reference

20 September 2017

1 reference